OCUL - A quarter of big progress should start to garner interest
OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would seem that the expectations at this point far underestimate the likely potential long-term adoption of DEXTENZA with expanded label and reimbursement codes in place. There is no doubt that DEXTENZA represents a step function improvement in an archaic and highly complex manual eye-drop regime, it should only be a matter of execution on the company's part to fully penetrate what should be a very sizable opportunity ($500 Million - $1 Billion plus) in post surgical inflammation and pain. As the market warms up to this reality, current valuation should expand significantly.
OCUL trade ideas
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILYOcular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
SHORT INTEREST
8.24M 07/15/19
P/E Current
-2.78
P/E Ratio (with extraordinary items)
-2.92
Average Recommendation: OVERWEIGHT
Average Target Price: 9.67
OCUL price target 3.30 areayellow boxes are showing similar drop of price %
retracement to 0.382 area possible, due to downtrendline and support in NOV 2017
additonally 3.3 would fill the gap
1. Price needs to break 3.0 level before confirmation
2. TP ist not huge but still approx 10 % at 3.30 area even 3.50 possible
3. SL i would set pretty tight at 2.85 area
4. we might see similar price action like the red boxes, back to bottom and after that to the target
OCUL - Speculative smart money Momentum Long from $6.35 OCU was in our smart money watch list as it had Big insider buying on the 13th of August. It also seems forming a fallen angel formation. We think it has good upside potential.
John sent an intraday text alert on August 14th while this was at $6.35 indicating a possible entry zone. This has continued to hold and is something we continue to like as a long idea.
OCUL Breaking OutThis stock is breaking out on the weekly and daily charts . I will be entering on pullbacks. I think this stock has upside potential based on its upcoming drug FDA date, Dextenza. I like the data that has been released so far, seems positive. Let me know what you think, would love to discuss.
OCUL HAS BROKEN THE DOWNTREND: ONE MORE WAVE UP?OCUL has broken this small degree downtrend. If the level posted on chart holds i'm expectiong one more wave up. Put an eye on earnings (3/9/2017) for a potential catalyst for the next move. A strong breakdown under the level posted on chart invalidates this setup.